- Home
- AMS vs LPCN Comparison
AMS vs LPCN Comparison
Compare AMS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- LPCN
- Stock Information
- Founded
- AMS 1980
- LPCN 1997
- Country
- AMS United States
- LPCN United States
- Employees
- AMS N/A
- LPCN N/A
- Industry
- AMS Medical Specialities
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- LPCN Health Care
- Exchange
- AMS Nasdaq
- LPCN Nasdaq
- Market Cap
- AMS 17.2M
- LPCN 16.1M
- IPO Year
- AMS N/A
- LPCN N/A
- Fundamental
- Price
- AMS $2.51
- LPCN $2.89
- Analyst Decision
- AMS
- LPCN Strong Buy
- Analyst Count
- AMS 0
- LPCN 2
- Target Price
- AMS N/A
- LPCN $9.00
- AVG Volume (30 Days)
- AMS 4.0K
- LPCN 16.6K
- Earning Date
- AMS 08-13-2025
- LPCN 08-05-2025
- Dividend Yield
- AMS N/A
- LPCN N/A
- EPS Growth
- AMS N/A
- LPCN N/A
- EPS
- AMS N/A
- LPCN N/A
- Revenue
- AMS $29,251,000.00
- LPCN $4,208,119.00
- Revenue This Year
- AMS $5.06
- LPCN N/A
- Revenue Next Year
- AMS N/A
- LPCN N/A
- P/E Ratio
- AMS N/A
- LPCN N/A
- Revenue Growth
- AMS 26.61
- LPCN N/A
- 52 Week Low
- AMS $2.27
- LPCN $2.68
- 52 Week High
- AMS $3.59
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- AMS 51.57
- LPCN 39.08
- Support Level
- AMS $2.45
- LPCN $2.86
- Resistance Level
- AMS $2.53
- LPCN $3.00
- Average True Range (ATR)
- AMS 0.07
- LPCN 0.11
- MACD
- AMS 0.00
- LPCN -0.01
- Stochastic Oscillator
- AMS 36.67
- LPCN 12.28
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.